Investing in the future of the brain
INVESTMENT FOCUS
Neurotech & BCI
NeuroAI & Computational Biology
Precision & Digital Health
Platforms & Therapeutics
Human Augmentation
PURPOSE
We fund and support founders elevating health through innovative neuroscience and frontier technologies. PsyMed founders align healing, responsibility, and profitability.
INVESTMENT FOCUS
We invest in frontier technologies transforming the mental and brain illness epidemic into a flourishing future.
NEUROAI
Brain data, foundation models, and AI-driven discovery. AI that learns from the brain, and AI that helps us understand it.
NEUROTECH & BCI
Implants, stimulation, wearables and neural interfaces that read and write to the brain and nervous system
PRECISION NEUROSCIENCE
Shifting from general approach for large populations to focus on individual-based clinical and biological characteristics
NEW MODALITIES
RNA, gene, and cell therapies, plus delivery technolgies, and interventions that transcend conventional small molecules
HUMAN AUGMENTATION
Technologies that improve cognition, focus, mood, and sleep, and keep the brain healthy as we age
NEUROMETABOLISM
Bidirectional relationship between metabolic processes and mental health, through diet, exercise, and gut microbiota can impact brain function.
PLATFORMS AND NOVEL
THERAPEUTICS
Horizontal platforms and novel compounds to treat brain and mental health conditions
DIGITAL HEALTH & THERAPEUTICS
Applications, wearables, and platforms that help patients treat, prevent, or manage a disease and enable personalized care
PORTFOLIO
ACQUIRED
BECKLEY PSYTECH
Short duration, rapid-acting psychedelics
MOTIF NEUROTECH
Minimally invasive bioelectronic solutions for the brain
SANMAI
Transcranial focused ultrasound for mental health
STEALTH MARKETPLACE
Marketplace for transformational mental health modalities
STEALTH NEUROTECH
Biohybrid brain-computer interfaces
STEALTH HEALTHCARE
Integrated solution for cancer-specific behavioral health
STEALTH BIOTECH
AI-guided polypharmacology engine
STEALTH BIOTECH
Virtual organelle models
STEALTH BIOTECH
Precision biologics for neuroinflammation
STEALTH BIOTECH
Patient-derived bio and health data for AI models
STEALTH NEUROAI
Brain data to train better AI
STEALTH NEUROTECH
Non-invasive devices people actually wear
STEALTH BIOTECH
New modality that gets inside neurons and breaks what kills them
PEOPLE
Matias Serebrinsky
General Partner & Co-Founder
Matias is an investor, founder, and ecosystem builder. He previously led NVIDIA Inception North America, an accelerator for AI startups. Before that, he co-founded CookUnity, a foodtech company that has delivered 100+ million meals to date. Matias is the co-host of Business Trip.
Greg Kubin
General Partner & Co-Founder
Greg is a community builder, investor, and founder. He is a co-host of Business Trip, a podcast exploring the future of mental health and wellness. Over 20 investments in mental health companies. Co-founded HelloSponsor, a SaaS platform (AngelPad '15). Ex-Morgan Stanley, Viacom.
Danny Carbonero PhD
Investment Associate
Danny is an investor and engineer. He previously worked at Breakout Ventures. He holds a PhD in Biomedical Engineering from Boston University, where he was an NIH F31 Fellow, with a research focus on computational neuroscience. While at BU, he helped lead Nucleate Boston.
Martina Galdos
Operations Lead
Martina is an operations professional focused on driving execution in fast-growing companies. She has worked across operations, sales enablement, and product marketing at multiple startups. Her priority at PsyMed is to advance operational excellence by applying AI.
Dina Burkitbayeva MBA/MS
Co-Founder
CEO at Freedom Biosciences, developing next-generation neuropsychiatric therapeutics. Co-founder at PsyMed.
Tim Gardner PhD
Venture Partner
Neuroscientist. Chair of Bioengineering at the University of Oregon. Previously a founding member of Neuralink.
Negin Mohktari PhD
Venture Partner
Biotech investor. Previously a Partner at Bioluminescence Ventures and Senior Associate at Genoa Ventures.
John Krystal
MD
Advisor
Translational Psychiatry, and Neuroscience at Yale University School of Medicine. Chief of Psychiatry at Yale-New Haven Hospital.
Graham Pechenik JD
Advisor
Legal/IP. Patent attorney. JD from NYU and BS in biochemistry & cognitive neuroscience from UCSD.
Jacob Robinson PhD
Advisor
Neurotech. CEO and Co-Founder of Motif Neurotech. Professor of Electrical and Computer Engineering at Rice University.
Chrystal Mavros PhD
Advisor
Microbiology at Columbia University focused on gene therapy, gut-brain, next-gen sequencing, and postmortem brain analysis.
Alex Amen PhD
Advisor
Biomedical scientist. Gene and Cell Therapies. Director of Asset Acquisition at BridgeBio. Postdoctoral training in the Doudna lab.
Building at the frontier of neuro or looking to get involved as an investor?
SEND US AN EMAIL
